Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
about
Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cellsCIViC databaseRelationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer linesEnhancing the evaluation of PI3K inhibitors through 3D melanoma models.MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.ETS-targeted therapy: can it substitute for MEK inhibitors?K-RasV14I recapitulates Noonan syndrome in mice.Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanomaBRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells.A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanomaYY1 regulates melanoma tumorigenesis through a miR-9 ~ RYBP axisA simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancerThe Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options.Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.Current management of advanced melanoma: a transformed landscape.Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.Personalized oncology: genomic screening in phase 1.Conceptual Knowledge Discovery in Databases for Drug Combinations Predictions in Malignant MelanomaFuture of combination therapy with dabrafenib and trametinib in metastatic melanoma.Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.Ocular toxicities of MEK inhibitors and other targeted therapies.Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.Engineering and cytosolic delivery of a native regulatory protein and its variants for modulation of ERK2 signaling pathway.Current Development Status of MEK Inhibitors.Emerging and investigational therapies for neuroblastoma.Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo.Acanthoma planoepitheliale hyperkeratoticum, lesions associated with BRAF inhibitor in metastatic melanoma.Small Molecules Drive Big Improvements in Immuno-Oncology Therapies.The Forecast Is Bright: Recent Advances in Melanoma Treatment.BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells.New features in MEK retinopathy
P2860
Q27347800-1739BC39-3202-4009-AE7B-E3A03F80D3E9Q27612411-3B367D2B-8A38-48C8-8C74-15CCC2745B1EQ28542662-B49F2B0A-56C3-410D-BE75-B792BA0A5D69Q30746265-7857FD2D-E550-4CCE-9E01-D9D6E72DB325Q33566681-595DABAF-82CC-4A40-A83D-35596DB4EF6AQ33638827-1BD13317-555F-474D-B512-2BA2B3879E83Q34581270-7363740D-9CA2-417C-B5E0-055CDD8102EAQ34786402-9E9B72A2-AF7E-4D45-96DE-4686A914A0DDQ35140116-693C756D-3A93-4F2B-A98F-C91AE450E28FQ35550099-5D4FC53E-5C43-4C99-9939-A21F1133B672Q35602111-6B79907E-6F1F-4A13-BCBB-35A515707B6CQ35879952-BC0B8B61-EBB0-4EC3-B2CD-7E53AD431052Q35987286-A74DD674-A53F-4984-83E7-8B6DD8DF42A0Q36102807-182D07BA-8842-4993-B63C-74997A67F7E8Q36260662-080BCCD0-151E-45AD-83A9-52C3E40AD396Q37051433-89270447-AC20-4966-B25D-9DB9B1D1C327Q38212935-9BE928E0-4948-4758-A0F0-801B5F0D2DB5Q38228386-451EEF34-CC1C-4E9F-9414-5686B6AB4C2AQ38232150-DA946C2F-C626-41D6-9821-54CEE74C2926Q38459361-60BB220C-DCB7-44CC-AA2F-63043CC804DBQ38578960-ECED2C29-1916-4872-ABB8-DBF2C81687FCQ38585847-93358851-3B67-498D-AEF3-DAC2B72E2228Q38764273-C5F95177-81D8-4B92-A857-03E981C33557Q38840383-ABF5A830-61D5-470F-91BE-A46F3CAE2D48Q38968155-8FCD6D74-7CCA-427F-964D-66E170308C1DQ41962845-63103CBD-CD6B-4099-A2A6-30049D2518F9Q47250549-F160ECE3-F3F8-4A7D-897B-DF794E78BA1AQ47735535-C3818CD2-5276-4F0C-B69E-815952511456Q50073387-4A14786B-DA41-4D2E-8FD6-D747A44008E9Q50118866-436BECBB-4D02-4D4E-BC06-244D96618424Q50250126-2FD607B1-3B38-4FC8-94B5-A8E113DF3896Q53047113-3B95C9B2-3F0F-4992-8BEA-510656004B02Q54252869-7E59E093-985E-4763-AC60-C9130AFEFBAFQ55467257-EDA269B9-DD64-439A-9983-BBD5331C5286Q58739317-63298973-2C67-4FDD-AA6E-B91E658E3B2A
P2860
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
@ast
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
@en
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
@nl
type
label
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
@ast
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
@en
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
@nl
prefLabel
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
@ast
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
@en
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
@nl
P1476
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
@en
P2093
Alexander M Menzies
Georgina V Long
P304
P356
10.1158/1078-0432.CCR-13-2054
P407
P577
2014-04-15T00:00:00Z